SCHEMBL3993939

SCHEMBL3993939

CCCCOC(=O)CC(C)N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.48
ALDH1A1 P00352 1/20 0.48
ATM Q13315 1/20 0.45
DGKA P23743 1/20 0.44
HTR2C P28335 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
TSHR P16473 3/20 0.42
HPGD P15428 1/20 0.42
RAD52 P43351 1/20 0.42
FAAH O00519 1/20 0.41
HCAR2 Q8TDS4 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
PDE4D Q08499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19443240 1.00 NAAA (0.48) NAAAALDH1A1ATMDGKAHTR2C
SCHEMBL14315394 0.94 NAAA (0.57) NAAAALDH1A1DGKAHTR2CNPSR1
SCHEMBL3689952 0.92 NAAA (0.60) NAAADGKAHTR2CNPSR1L3MBTL1
SCHEMBL6437102 0.88 NAAA (0.38) NAAAALDH1A1DGKAHTR2CNPSR1
Hydrochloric Acid SCHEMBL28313226 0.86 L3MBTL1 (0.37) NAAAALDH1A1DGKAHTR2CNPSR1
SCHEMBL13533767 0.85 NAAA (0.46) NAAAALDH1A1ATMDGKAHTR2C
SCHEMBL6222496 0.84 NAAA (0.48) NAAAALDH1A1ATMDGKAHTR2C
SCHEMBL95383 0.83 ALDH1A1 (0.52) NAAAALDH1A1ATMDGKAHTR2C
SCHEMBL28117429 0.83 ALDH1A1 (0.52) NAAAALDH1A1ATMDGKAHTR2C
SCHEMBL1866046 0.83 ALDH1A1 (0.52) NAAAALDH1A1ATMDGKAHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054992-B1 PROTEIN-POLYMER-DRUG CONJUGATES ASANA BIOSCIENCES LLC (US) 2019-08-14 EP disclosed
EP-3054991-B1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS INC (US) 2019-04-03 EP disclosed
EP-2928504-B1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS INC (US) 2019-02-20 EP disclosed
EP-2931316-B1 HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES MERSANA THERAPEUTICS INC (US) 2019-02-20 EP disclosed
US-9849191-B2 Protein-polymer-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2017-12-26 US disclosed
US-20170348424-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2017-12-07 US disclosed
US-9808528-B2 Protein-polymer-drug conjugates and methods of using same MERSANA THERAPEUTICS, INC. (US) 2017-11-07 US disclosed
US-9770519-B2 Protein-polymer-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2017-09-26 US disclosed
US-20170119896-A1 TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF MERSANA THERAPEUTICS, INC. 2017-05-04 US disclosed
EP-2717916-B1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS INC (US) 2017-03-08 EP disclosed
US-8821850-B2 Protein-polymer-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2014-09-02 US disclosed
US-8815226-B2 Protein-polymer-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2014-08-26 US disclosed
US-8808679-B2 Auristatin compounds and conjugates thereof MERSANA THERAPEUTICS, INC. (US) 2014-08-19 US disclosed
WO-2014093394-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. (US) 2014-06-19 WO disclosed
WO-2014093640-A1 HYDROXY-POLMER-DRUG-PROTEIN CONJUGATES MERSANA THERAPEUTICS,INC. (US) 2014-06-19 WO disclosed
US-20140134127-A1 Protein-Polymer-Drug Conjugates MERSANA THERAPEUTICS, INC. (US) 2014-05-15 US disclosed
US-20140017265-A1 Terminally Modified Polymers and Conjugates Thereof MERSANA THERAPEUTICS, INC. 2014-01-16 US disclosed
WO-2014008375-A1 TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF MERSANA THERAPEUTICS, INC. (US) 2014-01-09 WO disclosed
US-20130101546-A1 Protein-Polymer-Drug Conjugates MERSANA THERAPEUTICS, INC. (US) 2013-04-25 US disclosed
WO-2009069132-A2 NOVEL REVERSE TRANSCRIPTASE INHIBITORS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348424-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, CLTB, BRAP NAAA 3420/4885ALDH1A1 3556/4885ATM 3204/4885
US-20140134127-A1 Protein-Polymer-Drug Conjugates PBRM1, CLTB, BRAP NAAA 3420/4885ALDH1A1 3556/4885ATM 3204/4885
US-20140017265-A1 Terminally Modified Polymers and Conjugates Thereof MALT1, ALG1, PRMT3 NAAA 4202/4885ALDH1A1 2397/4885ATM 2935/4885
US-20170119896-A1 TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF MALT1, ALG1, PRMT3 NAAA 4202/4885ALDH1A1 2397/4885ATM 2935/4885
US-20130101546-A1 Protein-Polymer-Drug Conjugates PBRM1, CLTB, BRAP NAAA 3360/4885ALDH1A1 3507/4885ATM 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.